Tender detail
Non-exclusive discount agreement for botulinum toxin type A medicines (incobotulinum only), 2026–2028
Summary
DAK-Gesundheit intends to conclude non-exclusive discount agreements with pharmaceutical companies for medicines containing the active ingredient botulinum toxin type A, incobotulinum only (ATC M03AX21). The agreements will run from 1 December 2026 to 30 November 2028 and will end automatically when a new exclusive agreement takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.